Clinical trials: Challenge Test
Food Hypersensitivity
Food Allergy Diagnostic Test Response to Previous Oral Challenge Response
The objective of this study is to compare the ocular response to CAC (using food allergen sensitive patients) to the systemic response of a previously performed oral food allergen challenge in the same subjects.
- Trial name
- NCT03693456
- Testing
- Conjunctival Allergen Challenge
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Asthma
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair
- Trial name
- NCT00624832
- Testing
- Xolair
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis
Congenital Sucrase-Isomaltase Deficiency
Adult Pilot Study for Reference Ranges and Optimal Cut-offs for the Sucrose Challenge Test and Sucrose Breath Test
An adult pilot study to establish the normal reference range and optimal cutoffs for the oral 50g Sucrose Challenge Test (SCT) and the 50g 13C-Sucrose Breath Test (CBT) for patients with CSID and healthy controls.
- Trial name
- NCT05045495
- Testing
- Sucrose Hydrogen Methane Breath Test
- Where
- United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- QOL Medical, LLC
Randomised Clinical Trial, Double Blind
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 administrations of VLPDEN-02 or control at days 0, 28, and 56.
- Conditions
- Randomised Clinical Trial, Double Blind, Dengue, Challenge Test
- Trial name
- NCT07831473
- Testing
- VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VLP Therapeutics
Asthma
Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing
The study compares Buventol® Easyhaler® and Bufomix® Easyhaler® to the current standard treatment during methacholine challenge test. The trial will also provide inspiratory flow profile data for Easyhaler inhaler.
- Trial name
- EASYRELIEF (NCT05084222)
- Testing
- Buventol® Easyhaler® 200 µg/inhalation dmDPI, Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI, Ventoline® Evohaler® 100 µg/inhalation pMDI
- Where
- 2 sites in Finland
- Volunteers
- 180 people
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma
The main objective of this study is to evaluate the safety and tolerability of multiple fixed doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).
- Trial name
- NCT00590720
- Testing
- MEDI528 50 mg
- Where
- 12 sites in United States, Canada
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Idiopathic Parkinson Disease
Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease
CVXL-0107 a glutamate release inhibitor, has shown evidence of antiparkinsonian and antidyskinetic activity in a macaque model and has shown a significant effect on the UPDRS-III (Movement Disorder Society - Unified Parkinson's…
- Trial name
- NCT02641054
- Testing
- CVXL-0107, Levodopa
- Where
- France
- Volunteers
- 21 people
- Sponsor
- CleveXel Pharma